CCND2 and skin basal cell carcinoma: The potential use of crizotinib in the treatment of BCC has been evaluated in vitro, with crizotinib reducing keratinocyte proliferation in part by suppressing the expression of signaling molecules downstream in the SHH pathway, GLI1 and CCND2 [114].